Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Q3 2024 Earnings Presentation
17 slides from Medipharm Labs's earnings presentation, Nov 14, 2024
Slide 1: Pharmaceutical Quality Cannabis Products – Q3 2024
Pharmaceutical Quality Cannabis Products – Q3 2024 November 14, 2024 | medipharmlabs.com TSX: LABS | OTCQX: MEDIF | FSE: MLZ
Slide 2: Cautionary Notes
Cautionary Notes The information contained in this corporate presentation (“Presentation”) of MediPharm Labs Corp. (“MediPharm”, the “Company”, “we”, “us”, or “our”) has been prepared for informational purposes only regarding the business of MediPharm and should be read together with the more detail
Slide 3: Company Highlights
Company Highlights Established Growing International Expanding Canadian Solid Financial Results Pharmaceutical Platform Medical Business Business Income Statement • The first commercial natural • Completed shipments to • Innovative, premium product • Growing revenues. extractor in North America cust
Slide 4: Uniquely Certified for Pharmaceutical Cannabis Industry
Uniquely Certified for Pharmaceutical Cannabis Industry DRUG ESTABLISHMENT LICENSE INTERNATIONAL GMP CANNABIS DRUG LICENSE Allows us to manufacture and sell API and Registered and Inspected site with US FDA. EU GMP certified Issued by Health Canada for the manufacture Pharmaceutical Drug Products. c
Slide 5: Where MediPharm Labs Wins
Where MediPharm Labs Wins MediPharm is well positioned for success where regulations are strict, and compliance standards are most challenging PHARMACEUTICAL CANNABIS INTERNATIONAL MEDICAL CANADIAN ADULT USE CANADIAN MEDICAL MARKET Market: Estimated sales of the major Market: Estimated at $12 billio
Slide 6: Customers in Every Pharmaceutical Commercialization Path
Customers in Every Pharmaceutical Commercialization Path LONG TERM, PROFITABLE RELATIONSHIPS NOVEL DRUG APPLICATION (NDAs) ABBREVIATED NEW DRUG APPLICATION (ANDAs) FDA 505 B2 Completed first Pharma API sales in Q4 2021. Launched Dronabinol Pharmaceutical API in Germany in 2023. Supporting 10 ongoing
Slide 7: Our International Medical Cannabis Business
Our International Medical Cannabis Business GERMANY BRAZIL AUSTRALIA REST OF WORLD FY’23 market value estimate: $345 million FY’23 market value estimate: $70 million FY’23 market value estimate: $308 million MediPharm continues to expand global USD million (source: Prohibition Partners) USD million
Slide 8: Australian Medical Cannabis
Australian Medical Cannabis Established since 2018, Beacon Medical is a leading medical cannabis brand in Australia. The 6th best brand in sales in Expanded portfolio with GMP Prescribed by 300+ Future growth with renewed Australia. (1) vapes and oils in 2023. physicians. flower genetics and premium
Slide 9: German Medical Cannabis
German Medical Cannabis As of April 1, 2024 Germany has decriminalized cannabis and it is no longer regulated as a narcotic, allowing for rapid expansion in the medical market. MediPharm has operated in Germany since 2019. MediPharm has three business lines in Germany. Beacon Medical GMBH Business t
Slide 10: Canadian Medical
Canadian Medical MediPharm Labs is a Leading Company in Canadian Patient Product Sales and Services through our Canna Farms Medical platform Following the 2023 acquisition of VIVO Cannabis, MediPharm has moved closer to the patient with the addition of a medical cannabis sales platform and specializ
Slide 11: Our Canadian Adult Use and Wellness Business
Our Canadian Adult Use and Wellness Business • Quality, innovative products command premium prices. • Focus on highest quality, most-differentiated products. • #1 premium CBD oil in Canada.* * Source: Hifyre Quality You Can Trust www.medipharmlabs.com
Slide 12: Third Quarter – 2024 Highlights
Third Quarter – 2024 Highlights Select highlights for the three month and year-to-date period ending September 30, 2024 • Beacon branded growth strategy in international markets is expected to allow MediPharm to control revenue opportunity and build brand equity. International Growth • Refreshed Bea
Slide 13: MediPharm's growing revenue is diversified across geography, channel and product category
MediPharm’s growing revenue is diversified across geography, channel and product category Quality You Can Trust www.medipharmlabs.com Note: Diversification percentages based on Q3 2024 YTD revenue 13
Slide 14: MediPharm Labs approaching Breakeven Adjusted EBITDA
MediPharm Labs approaching Breakeven Adjusted EBITDA(1) MediPharm has made significant improvement over 2.5 years towards profitability Gross Profit and Adjusted EBITDA(1) continue to improve as MediPharm approaches profitability. (1) Adjusted EBITDA is a non-IFRS measure. See “Non-IFRS Measures”. T
Slide 15: Key Takeaways
Key Takeaways Corporate Pharmaceutical First Diversified and Strong Balance Development Cannabis Company Growing Sheet Opportunities Full suite of GMP production licenses Growing, diversified full line Product Peer-leading Financials with a strong Continued exploration of M&A for all product formats
Slide 16: THANK YOU
THANK YOU Follow Up Inquires investors@medipharmlabs.com
Slide 17: Additional Cautionary Notes
Additional Cautionary Notes ASSUMPTIONS. The Company made specific assumptions and relied on outside factors and considerations in this Presentation. See Q3 2024 MD&A available on SedarPlus.ca for full details, disclosures and risk factors. FUTURE ORIENTED FINANCIAL INFORMATION. To the extent any fo